NIVIA-Hemodynamics
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Mar 18, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The NIVIA-Hemodynamics trial is studying how well two different methods of checking heart function work in patients who are experiencing serious heart problems, such as cardiogenic shock or heart failure. The trial will compare a non-invasive method using ultrasound (pictures of the heart and lungs) with a traditional invasive method that involves inserting a special catheter (a thin tube) into the heart. This study aims to see if the non-invasive techniques can provide similar information about heart function without the need for a more invasive procedure.
To be eligible for this trial, patients must be admitted to the Cardiac Intensive Care Unit (CICU) and have a catheter placed as part of their standard care. If you qualify and choose to participate, you will undergo a non-invasive assessment using ultrasound right after the catheter placement and then again daily for the next few days. This trial is open to all genders and is currently recruiting participants aged 65 and older. It's important to note that if you're already part of another clinical trial with a treatment, you won’t be able to join this one.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with admitted to the CICU in whom PAC is inserted as standard of care,
- Exclusion Criteria:
- • Enrollment into another trial with an active treatment arm
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Filio Billia, MD PhD
Principal Investigator
UHN
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported